Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
TARPON SPRINGS, Fla., May 12, 2025 — Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company's CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company's DRP® companion diagnostic platform and conduct one-on-one meetings at the Pharma Partnering Summit US. The event is a business development and licensing conference for executives of biotechnology and pharmaceutical companies, taking place May 14–15 in San Diego, CA.
Registrants can request one-on-one meetings with Thomas Jensen, and more information about the summit can be found at the following link: https://pharma-partnering-summit.com/pps-wc.html
About Stenoparib
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, corporate presentation highlighting Allarity's clinical strategy and development progress for stenoparib. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements concerning clinical development progress, trial design and enrollment for stenoparib, the potential benefits of DRP®-guided therapy, and efforts to achieve regulatory milestones. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
[email protected]
Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
A Once-in-a-Decade Opportunity: 1 Super Growth Stock Down 48% to Buy Right Now and Hold for a Decade
Shares of software-as-a-service platform Nice remain nearly 50% below their 2021 highs. However, the company's leading position and burgeoning AI sales point to a promising future ahead. With its valuation near a decade low, Nice is buying back shares -- and investors should consider them too. 10 stocks we like better than Nice › While buying a roughed-up stock "on the dip" seems like a no-brainer, the unfortunate truth is that many of these embattled businesses may actually prove to be "falling knives." However, if investors prioritize high-quality, market-leading, innovative companies, buying the dip can occasionally make perfect sense. I'd argue this is especially true when the stock in question is trading at what appears to be a once-in-a-decade valuation, which is the case for the business we will examine today. Operating in three industry verticals buoyed by long-term megatrends, Nice (NASDAQ: NICE) and its artificial intelligence (AI) innovations could prove to be an excellent buy-the-dip candidate, especially since its stock is down 48% from its highs. Nice is a leading software-as-a-service (SaaS) business, providing AI-powered solutions to enterprises via its cloud platform. The company primarily serves three areas: Customer engagement (About 75% of sales): Nice offers end-to-end SaaS solutions that help clients automate their customer service operations while augmenting their human workforce with agentic AI. The cornerstone of this effort is its center-as-a-service (CCaaS) platform, which Forrester ranks as one of the leaders in this niche. Financial crime and compliance (15% of sales): Nice's AI-embedded tools help corporate customers battle fraud, money laundering, and suspicious activity while providing compliance and surveillance services. It uses machine learning to parse through mountains of financial data and AI to automate more mundane tasks. Many top U.S. and European banks use this service. Public safety and justice (10% of sales): In its smallest segment, Nice helps with emergency response optimization and digital evidence management. Nice and Axon Enterprise are the two leaders in this niche, according to IDC, acting like the Coca-Cola and PepsiCo to the public safety and justice market. Nice's offerings are used by 85% of U.S. and Canadian cities and 94% of the United Kingdom's police stations. Thanks to its leadership in these three niches -- and counting 85 of the Fortune 100 enterprises as customers -- Nice is an undeniable SaaS leader with sales in over 150 countries. Yet, despite this powerful presence, the company's growth story could still be in its early chapters. With fraud and money laundering schemes increasing in complexity by the day, digital evidence growing exponentially, and AI providing a tailwind in each market, Nice could be positioned for decades of growth if it can successfully harness the power of AI. Far and away, the most important thing for investors to watch going forward with Nice will be whether it remains an AI innovator, not a disruptee. The company is off to a tremendous start so far, with AI solutions at the forefront of its platform. In 2024, 97% of Nice's CXone Mpower contracts worth $1 million or more included AI offerings. This figure grew to 100% as of the first quarter of 2025, demonstrating that the company is, if nothing else, AI-first. Furthermore, while overall cloud revenue grew 12% in Q1, Nice's AI and self-service sales grew by 39%. This data point will be paramount to watch going forward, as this outsize growth suggests that Nice is leading the AI innovation race, rather than getting disrupted by it. Similarly, its cloud net retention rate of 111% highlights additional customer "buy-in." Measuring the spending of existing customers from last year to this year, this 11% increase indicates that the company is successfully upselling and cross-selling its new solutions, most likely AI-powered offerings. Despite reporting top-notch AI sales growth, Nice's shares slid following its Q1 earnings, mainly due to what the market deemed weak guidance. This drop leaves the company trading at just 14 times free cash flow (FCF). This price-to-FCF (P/FCF) ratio of 14 is near a decade-long low and is almost half of the company's historical average of 27. Even accounting for the dilutive effects of stock-based compensation, Nice trades at just 18 times FCF, far below the S&P 500's average P/FCF ratio, which is somewhere north of 30. Perhaps the biggest signal that Nice's valuation today may be a once-in-a-decade opportunity comes from management currently buying back shares at the fastest rate in the company's history. Nice is armed with more than $1 billion in net cash, compared to its market capitalization of $11 billion, so it could easily continue buying back shares at what looks like an incredible valuation. Altogether, Nice's combination of leadership positioning, AI integration, and discounted valuation makes it a super growth stock to buy on the dip. However, it'll be of the utmost importance to keep an eye on Nice's AI sales in each quarterly update and ensure the company remains the AI innovator, not the disruptee. Before you buy stock in Nice, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nice wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Josh Kohn-Lindquist has positions in Axon Enterprise and Coca-Cola. The Motley Fool has positions in and recommends Amazon, Axon Enterprise, and Nice. The Motley Fool recommends Gartner. The Motley Fool has a disclosure policy. A Once-in-a-Decade Opportunity: 1 Super Growth Stock Down 48% to Buy Right Now and Hold for a Decade was originally published by The Motley Fool
Yahoo
18 minutes ago
- Yahoo
'I Bought Netflix At $12 And Sold At $10. Now It's At $1,100, Says Scott Galloway, Hates When People Only Post Their Wins Online
Scott Galloway, the outspoken professor and entrepreneur, says he gets it wrong all the time—and he doesn't try to hide it. 'I bought Netflix at $12 and sold it at $10. Now it's at $1,100,' he said on a recent episode of the 'My First Million' podcast. 'I can't stand people who are constantly taking pictures of all their wins and posting them on social.' Despite that Netflix (NASDAQ:NFLX) miss, Galloway has racked up some big wins, mostly by betting on unpopular, overlooked assets. He says the best returns don't come from trendy stocks, but from distressed situations that smell, as he put it, 'like urine.' Don't Miss: Invest where it hurts — and help millions heal:.One of his best trades? Buying $10 million in FTX bankruptcy claims for $2.2 million after digging through the exchange's filings. He figured their investment in AI company Anthropic was worth much more than creditors realized. "Crypto took off, everything they had invested in went crazy," he said. 'Looks like we're going to get 160 cents on the dollar.' He admits there was risk, but also effort. 'I'm that guy who reads bankruptcy filings,' he said. Galloway's biggest return came from helping bring vape company NJOY out of bankruptcy. He initially put in $2.5 million. After the company received the U.S. Food and Drug Administration approval and was bought by Altria (NYSE:MO), his stake turned into $75 million. 'We almost went to zero two or three times,' he said. 'But that was hands down my best investment.' Trending: Another win came from dying yellow pages company Dex Media. He got in for about $4 million and sold after the business successfully pivoted into software. "What is less sexy than Yellow Pages?" he said. Still, he doesn't shy away from his losses. He once invested $5 million in a healthcare texting company that went to zero in just 18 months. And he left $2 million on the table after selling covered calls on a stock that jumped right after earnings. Galloway is now moving away from U.S. equities, citing sky-high valuations and political instability. "[If] you think you're diversified because you're in an index fund, you're not, because I believe the U.S. is going to go flat in the next decade," he said. 'I'm going to be almost entirely out of the U.S. market within three or four months.' He's especially bullish on Europe, clarifying how everyone thinks Europe is overregulated and boring, but that's exactly when you invest. 'When something's been left for dead,' he said. Read Next: These five entrepreneurs are worth $223 billion – Here's what Americans think you need to be considered 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NETFLIX (NFLX): Free Stock Analysis Report ALTRIA GROUP (MO): Free Stock Analysis Report This article 'I Bought Netflix At $12 And Sold At $10. Now It's At $1,100, Says Scott Galloway, Hates When People Only Post Their Wins Online originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Aviation Analyst: SpaceX Starship grounded after third test flight explosion
CHARLOTTE () — Another blow for Elon Musk's SpaceX. Its giant Starship is grounded yet again after exploding during another test flight, the third time this year. Chief transportation correspondent MayCay Beeler explains what went into the decision. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
